On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...
In a turbulent market environment, Vincerx Pharma, Inc. (VINC) stock has reached its 52-week low, trading at $1.3. According to InvestingPro analysis, the company maintains a healthy current ratio of ...
Investing.com - Vincerx Pharma reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. Vincerx Pharma announced ...
Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.
Vincerx Pharma, Inc. (Nasdaq: VINC) today announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results